---
title: "Natural Alternatives Reassigns CEO Role to Lead Swiss Operations"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/279993611.md"
description: "Natural Alternatives International (NAII) has reassigned CEO Mark A. LeDoux to lead its Swiss operations, reducing his U.S. salary from $475,000 to $255,000 while establishing a new role with a base salary of 170,000 CHF in Switzerland. This restructuring aims to enhance global revenue and operations. Analysts rate NAII stock as a Sell with a $2.50 price target, citing weak profitability and increased leverage despite a revenue rebound. The company focuses on nutritional supplements and operates in both the U.S. and Switzerland, with a current market cap of $16.18M."
datetime: "2026-03-20T21:06:43.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/279993611.md)
  - [en](https://longbridge.com/en/news/279993611.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/279993611.md)
---

# Natural Alternatives Reassigns CEO Role to Lead Swiss Operations

### Claim 70% Off TipRanks Premium

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential

Natural Alternatives International ( (NAII) ) has provided an update.

Natural Alternatives International, Inc. amended Chief Executive Officer Mark A. LeDoux’s employment agreement effective May 1, 2026, cutting his base salary from $475,000 to $255,000 and reducing certain officer benefits. At the same time, LeDoux entered into a separate employment agreement to serve as Managing Director of the company’s Swiss subsidiary, Natural Alternatives International, Inc. Europe, with a base salary of 170,000 CHF per year.

The company structured the U.S. and Swiss agreements so that LeDoux’s total compensation remains roughly unchanged, subject to currency fluctuations, while requiring him to spend at least half his time in Switzerland. By having its CEO concurrently lead the Swiss unit and remain board chair of both entities, Natural Alternatives aims to expand worldwide revenue and enhance its Swiss operations to give customers more opportunities to grow inside and outside the U.S.

The most recent analyst rating on (NAII) stock is a Sell with a $2.50 price target. To see the full list of analyst forecasts on Natural Alternatives International stock, see the NAII Stock Forecast page.

**Spark’s Take on NAII Stock**

According to Spark, TipRanks’ AI Analyst, NAII is a Neutral.

The score is held down primarily by weak profitability (operating and net losses with low gross margin) and increased leverage, despite a strong TTM revenue rebound. Technical signals also remain soft (negative MACD, sub-50 RSI, and price below short-term moving averages). Positive operating and free cash flow provide some support, but losses and volatility keep the overall profile pressured.

To see Spark’s full report on NAII stock, click here.

**More about Natural Alternatives International**

Natural Alternatives International, Inc. operates in the nutritional supplements and wellness sector, manufacturing and supplying dietary supplement products and related formulations. The company serves global customers through its operations in the U.S. and its wholly owned Swiss subsidiary, Natural Alternatives International, Inc. Europe, reflecting a strategic focus on international markets and expanded production capabilities.

**Average Trading Volume:** 18,731

**Technical Sentiment Signal:** Strong Sell

**Current Market Cap:** $16.18M

### Related Stocks

- [NAII.US](https://longbridge.com/en/quote/NAII.US.md)

## Related News & Research

- [Natural Alternatives International, Inc. Announces 2026 Q3 and YTD Results | NAII Stock News](https://longbridge.com/en/news/286893119.md)
- [Hogs Look to Tuesday Trade](https://longbridge.com/en/news/286913138.md)
- [Jack Antonoff tells people who are making AI art to 'drive right off that cliff'](https://longbridge.com/en/news/286592426.md)
- [Coffee Prices Rise as ICE Inventories Shrink](https://longbridge.com/en/news/286953826.md)
- [12:46 ETEyePromise Introduces Heyedrate™ Clinical: A Next Generation Artificial Tear](https://longbridge.com/en/news/286800296.md)